Business
INOVIO Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
10 of 11 patients (91%) had a reduction in number of surgical interventions, measured from Day 0 to one year following initial treatment; 4 of the 10 patients
About this update from Inovio Pharmaceuticals, Inc.
[{"type":"text","content":"10 of 11 patients (91%) had a reduction in number of surgical interventions, measured from Day 0 to one year following initial treatment; 4 of the 10 patients did not need any surgeryTreatment with INO-3107 achieved statistical significance based on clinical endpoint of reduction in overall number of surgical interventions compared with previous yearINO-3107 was well-tolerated and immunogenic, with efficacy and safety results for second cohort consistent with first cohortPatients in second cohort were administered INO-3107 using the exploratory side port needlePLYMOUTH MEETING, Pa., Feb. 16, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced positive preliminary results from the second cohort of its Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults. In the second cohort of 11 patients who were administered INO-3107 via the exploratory side port needle, 10 of the 11 patients (91%) saw a reduction in surgical interventions in the year following initial treatment, with measurement beginning at Day 0, the start of trial therapy. Of these 10 patients, four did not require surgery. There was a statistically significant median decrease of three surgical interventions when comparing the year following treatment to the year prior. In the year prior to treatment, the number of surgical interventions for these 11 patients ranged between 2 and 8, and the median was 5. INO-3107 was well-tolerated and immunogenic among patients in the second cohort. The safety and efficacy results for the second cohort were consistent with results announced for the first cohort in October 2022.\n\"These results from the second cohort confirm previous data that show INO-3107 is well-tolerated, immunogenic and has the potential to improve patients' lives by reducing the need for painful surgery,\" said Dr. Jeffrey Skolnik, INOVIO's Senior Vice President of Clinical Development. \"We will continue to engage with regulators regarding our development plans for INO-3107 and look forward to publishing and presenting our findings from the complete data set soon.\"\n\"Many patients with RRP n...